{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:19:11Z","timestamp":1790299151898,"version":"4.1.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"ministry of science and technology, taiwan","doi-asserted-by":"publisher","award":["108-2314-B-006 -079 -MY3"],"award-info":[{"award-number":["108-2314-B-006 -079 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Huntington\u2019s disease (HD) is one of neurodegenerative diseases, and is defined as a monogenetic disease due to the mutation of\n                    <jats:italic>Huntingtin<\/jats:italic>\n                    gene. This disease affects several cellular functions in neurons, and further influences motor and cognitive ability, leading to the suffering of devastating symptoms in HD patients. MicroRNA (miRNA) is a non-coding RNA, and is responsible for gene regulation at post-transcriptional levels in cells. Since one miRNA targets to several downstream genes, it may regulate different pathways simultaneously. As a result, it raises a potential therapy for different diseases using miRNAs, especially for inherited diseases. In this review, we will not only introduce the update information of HD and miRNA, but also discuss the development of potential miRNA-based therapy in HD. With the understanding toward the progression of miRNA studies in HD, we anticipate it may provide an insight to treat this devastating disease, even applying to other genetic diseases.\n                  <\/jats:p>","DOI":"10.1186\/s12929-021-00755-1","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T01:24:21Z","timestamp":1629336261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington's disease"],"prefix":"10.1186","volume":"28","author":[{"given":"Chih-Wei","family":"Tung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Chin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Hsun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1601-3653","authenticated-orcid":false,"given":"Shang-Hsun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"issue":"15 Supplement","key":"755_CR1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1212\/WNL.94.15_supplement.954","volume":"94","author":"G Yohrling","year":"2020","unstructured":"Yohrling G, Raimundo K, Crowell V, Lovecky D, Vetter L, Seeberger L. Prevalence of Huntington\u2019s Disease in the US (954). Neurology. 2020;94(15 Supplement):954.","journal-title":"Neurology"},{"issue":"6","key":"755_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"THsDCR Group","year":"1993","unstructured":"Group THsDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell. 1993;72(6):971\u201383.","journal-title":"Cell"},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/7854_2010_105","volume":"7","author":"SH Yang","year":"2011","unstructured":"Yang SH, Chan AW. Transgenic animal models of Huntington\u2019s disease. Curr Top Behav Neurosci. 2011;7:61\u201385.","journal-title":"Curr Top Behav Neurosci"},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.parkreldis.2018.11.009","volume":"61","author":"M Oosterloo","year":"2019","unstructured":"Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE. Clinical and genetic characteristics of late-onset Huntington\u2019s disease. Parkinsonism Relat Disord. 2019;61:101\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"755_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/JHD-170270","volume":"7","author":"OK Solberg","year":"2018","unstructured":"Solberg OK, Filkukov\u00e1 P, Frich JC, Feragen KJB. Age at death and causes of death in patients with Huntington disease in Norway in 1986\u20132015. J Huntingtons Dis. 2018;7(1):77\u201386.","journal-title":"J Huntingtons Dis"},{"issue":"7","key":"755_CR6","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","volume":"19","author":"CA Gutekunst","year":"1999","unstructured":"Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ. Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology. J Neurosci. 1999;19(7):2522\u201334.","journal-title":"J Neurosci"},{"issue":"5 Pt 2","key":"755_CR7","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1523\/JNEUROSCI.15-05-03775.1995","volume":"15","author":"C Portera-Cailliau","year":"1995","unstructured":"Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci. 1995;15(5 Pt 2):3775\u201387.","journal-title":"J Neurosci"},{"issue":"3","key":"755_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1755-5949.2010.00134.x","volume":"16","author":"VM Andr\u00e9","year":"2010","unstructured":"Andr\u00e9 VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington\u2019s disease: a balancing act. CNS Neurosci Ther. 2010;16(3):163\u201378.","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"755_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/1073858404266777","volume":"10","author":"SH Li","year":"2004","unstructured":"Li SH, Li XJ. Huntingtin and its role in neuronal degeneration. Neuroscientist. 2004;10(5):467\u201375.","journal-title":"Neuroscientist"},{"issue":"19","key":"755_CR10","doi-asserted-by":"publisher","first-page":"e2045","DOI":"10.1212\/WNL.0000000000008906","volume":"94","author":"AM Glidden","year":"2020","unstructured":"Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER, Heatwole CR. Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology. 2020;94(19):e2045\u201353.","journal-title":"Neurology"},{"issue":"2","key":"755_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JHD-200451","volume":"10","author":"C Lang","year":"2021","unstructured":"Lang C, Gries C, Lindenberg KS, Lewerenz J, Uhl S, Olsson C, Samzelius J, Landwehrmeyer GB. Monitoring the motor phenotype in Huntington's disease by analysis of keyboard typing during real life computer use. J Huntingtons Dis. 2021;10(2):259\u201368.","journal-title":"J Huntingtons Dis"},{"issue":"48","key":"755_CR12","doi-asserted-by":"publisher","first-page":"18540","DOI":"10.1074\/jbc.RA118.004621","volume":"293","author":"SM DeGuire","year":"2018","unstructured":"DeGuire SM, Ruggeri FS, Fares MB, Chiki A, Cendrowska U, Dietler G, Lashuel HA. N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting. J Biol Chem. 2018;293(48):18540\u201358.","journal-title":"J Biol Chem"},{"key":"755_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113396","volume":"332","author":"NH Skotte","year":"2020","unstructured":"Skotte NH, Pouladi MA, Ehrnhoefer DE, Huynh K, Qiu X, Nielsen SMB, Nielsen TT, Norremolle A, Hayden MR. Compromised IGF signaling causes caspase-6 activation in Huntington disease. Exp Neurol. 2020;332: 113396.","journal-title":"Exp Neurol"},{"issue":"1","key":"755_CR14","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1038\/s41467-020-16318-1","volume":"11","author":"H Yang","year":"2020","unstructured":"Yang H, Yang S, Jing L, Huang L, Chen L, Zhao X, Yang W, Pan Y, Yin P, Qin ZS, Tang B, Li S, Li XJ. Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form. Nat Commun. 2020;11(1):2582.","journal-title":"Nat Commun"},{"issue":"6","key":"755_CR15","doi-asserted-by":"publisher","first-page":"10519","DOI":"10.1002\/jcb.28338","volume":"120","author":"SB Priya","year":"2019","unstructured":"Priya SB, Gromiha MM. Structural insights into the aggregation mechanism of huntingtin exon 1 protein fragment with different polyQ-lengths. J Cell Biochem. 2019;120(6):10519\u201329.","journal-title":"J Cell Biochem"},{"issue":"1","key":"755_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00429-012-0401-x","volume":"218","author":"PH Cheng","year":"2013","unstructured":"Cheng PH, Li CL, Her LS, Chang YF, Chan AW, Chen CM, Yang SH. Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein. Brain Struct Funct. 2013;218(1):283\u201394.","journal-title":"Brain Struct Funct"},{"issue":"4","key":"755_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bpa.12191","volume":"25","author":"LS Her","year":"2015","unstructured":"Her LS, Lin JY, Fu MH, Chang YF, Li CL, Tang TY, Jhang YL, Chang CY, Shih MC, Cheng PH, Yang SH. The differential profiling of ubiquitin-proteasome and autophagy systems in different tissues before the onset of Huntington\u2019s disease models. Brain Pathol. 2015;25(4):481\u201390.","journal-title":"Brain Pathol"},{"key":"755_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2202-14-88","volume":"14","author":"J Kocerha","year":"2013","unstructured":"Kocerha J, Liu Y, Willoughby D, Chidamparam K, Benito J, Nelson K, Xu Y, Chi T, Engelhardt H, Moran S, Yang SH, Li SH, Li XJ, Larkin K, Neumann A, Banta H, Yang JJ, Chan AW. Longitudinal transcriptomic dysregulation in the peripheral blood of transgenic Huntington\u2019s disease monkeys. BMC Neurosci. 2013;14:88.","journal-title":"BMC Neurosci"},{"issue":"5","key":"755_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4161\/auto.6.5.12336","volume":"6","author":"XJ Li","year":"2010","unstructured":"Li XJ, Li H, Li S. Clearance of mutant huntingtin. Autophagy. 2010;6(5):663\u20134.","journal-title":"Autophagy"},{"key":"755_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s40064-015-1400-1","volume":"4","author":"MH Fu","year":"2015","unstructured":"Fu MH, Li CL, Lin HL, Chen PC, Calkins MJ, Chang YF, Cheng PH, Yang SH. Stem cell transplantation therapy in Parkinson\u2019s disease. Springerplus. 2015;4:597.","journal-title":"Springerplus"},{"key":"755_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fnmol.2017.00196","volume":"10","author":"JY Hsu","year":"2017","unstructured":"Hsu JY, Jhang YL, Cheng PH, Chang YF, Mao SH, Yang HI, Lin CW, Chen CM, Yang SH. The truncated C-terminal fragment of mutant ATXN3 disrupts mitochondria dynamics in spinocerebellar ataxia type 3 models. Front Mol Neurosci. 2017;10:196.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"755_CR22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/jnr.24781","volume":"99","author":"VK Medala","year":"2021","unstructured":"Medala VK, Gollapelli B, Dewanjee S, Ogunmokun G, Kandimalla R, Vallamkondu J. Mitochondrial dysfunction, mitophagy, and role of dynamin-related protein 1 in Alzheimer's disease. J Neurosci Res. 2021;99(4):1120\u201335.","journal-title":"J Neurosci Res"},{"issue":"3","key":"755_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10863-010-9286-7","volume":"42","author":"YN Jin","year":"2010","unstructured":"Jin YN, Johnson GV. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr. 2010;42(3):199\u2013205.","journal-title":"J Bioenerg Biomembr"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.freeradbiomed.2020.11.031","volume":"163","author":"L Naia","year":"2021","unstructured":"Naia L, Carmo C, Campesan S, F\u00e3o L, Cotton VE, Valero J, Lopes C, Rosenstock TR, Giorgini F, Rego AC. Mitochondrial SIRT3 confers neuroprotection in Huntington\u2019s disease by regulation of oxidative challenges and mitochondrial dynamics. Free Radic Biol Med. 2021;163:163\u201379.","journal-title":"Free Radic Biol Med"},{"key":"755_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.freeradbiomed.2018.10.455","volume":"130","author":"IO Yusuf","year":"2019","unstructured":"Yusuf IO, Chen HM, Cheng PH, Chang CY, Tsai SJ, Chuang JI, Wu CC, Huang BM, Sun HS, Yang SH. Fibroblast growth factor 9 activates anti-oxidative functions of Nrf2 through ERK signalling in striatal cell models of Huntington\u2019s disease. Free Radic Biol Med. 2019;130:256\u201366.","journal-title":"Free Radic Biol Med"},{"key":"755_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104741","volume":"136","author":"M Cherubini","year":"2020","unstructured":"Cherubini M, Lopez-Molina L, Gines S. Mitochondrial fission in Huntington\u2019s disease mouse striatum disrupts ER-mitochondria contacts leading to disturbances in Ca(2+) efflux and Reactive Oxygen Species (ROS) homeostasis. Neurobiol Dis. 2020;136: 104741.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"755_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/JHD-170264","volume":"6","author":"JM Dubinsky","year":"2017","unstructured":"Dubinsky JM. Towards an understanding of energy impairment in Huntington\u2019s disease brain. J Huntingtons Dis. 2017;6(4):267\u2013302.","journal-title":"J Huntingtons Dis"},{"key":"755_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107705","volume":"219","author":"S Jamwal","year":"2020","unstructured":"Jamwal S, Blackburn JK, Elsworth JD. PPARgamma\/PGC1alpha signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol Therapy. 2020;219:107705.","journal-title":"Pharmacol Therapy."},{"issue":"9","key":"755_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2018.109","volume":"17","author":"B Boland","year":"2018","unstructured":"Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E, Pastores GM, Rubinsztein DC, Nixon RA, Duchen MR, Mallucci GR, Kroemer G, Levine B, Eskelinen EL, Mochel F, Spedding M, Louis C, Martin OR, Millan MJ. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2018;17(9):660\u201388.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"755_CR30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/aps.2018.11","volume":"39","author":"RJ Harding","year":"2018","unstructured":"Harding RJ, Tong YF. Proteostasis in Huntington\u2019s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol Sin. 2018;39(5):754\u201369.","journal-title":"Acta Pharmacol Sin"},{"issue":"7154","key":"755_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nature06022","volume":"448","author":"EJ Bennett","year":"2007","unstructured":"Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR. Global changes to the ubiquitin system in Huntington\u2019s disease. Nature. 2007;448(7154):704\u20138.","journal-title":"Nature"},{"issue":"6","key":"755_CR32","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1007\/s12035-020-02280-y","volume":"58","author":"ZN Huang","year":"2021","unstructured":"Huang ZN, Chen JM, Huang LC, Fang YH, Her LS. Inhibition of p38 mitogen-activated protein kinase ameliorates HAP40 depletion-induced toxicity and proteasomal defect in Huntington's disease model. Mol Neurobiol. 2021;58(6):2704\u201323.","journal-title":"Mol Neurobiol"},{"issue":"9","key":"755_CR33","doi-asserted-by":"publisher","first-page":"7382","DOI":"10.1007\/s12035-016-0247-y","volume":"54","author":"ZN Huang","year":"2017","unstructured":"Huang ZN, Her LS. The ubiquitin receptor ADRM1 modulates HAP40-induced proteasome activity. Mol Neurobiol. 2017;54(9):7382\u2013400.","journal-title":"Mol Neurobiol"},{"issue":"32","key":"755_CR34","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.1523\/JNEUROSCI.0806-16.2016","volume":"36","author":"T Zhao","year":"2016","unstructured":"Zhao T, Hong Y, Li S, Li XJ. Compartment-dependent degradation of mutant huntingtin accounts for its preferential accumulation in neuronal processes. J Neurosci. 2016;36(32):8317\u201328.","journal-title":"J Neurosci"},{"issue":"Pt A","key":"755_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.nbd.2017.10.002","volume":"109","author":"B Wang","year":"2018","unstructured":"Wang B, Zeng L, Merillat SA, Fischer S, Ochaba J, Thompson LM, Barmada SJ, Scaglione KM, Paulson HL. The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington\u2019s disease protein, huntingtin. Neurobiol Dis. 2018;109(Pt A):127\u201336.","journal-title":"Neurobiol Dis"},{"issue":"21","key":"755_CR36","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1038\/sj.emboj.7600426","volume":"23","author":"CI Holmberg","year":"2004","unstructured":"Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI. Inefficient degradation of truncated polyglutamine proteins by the proteasome. Embo J. 2004;23(21):4307\u201318.","journal-title":"Embo J"},{"issue":"6","key":"755_CR37","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1080\/15548627.2020.1760014","volume":"17","author":"PL Bratt\u00e5s","year":"2021","unstructured":"Bratt\u00e5s PL, Hersbach BA, Madsen S, Petri R, Jakobsson J, Pircs K. Impact of differential and time-dependent autophagy activation on therapeutic efficacy in a model of Huntington disease. Autophagy. 2021;17(6):1316\u201329.","journal-title":"Autophagy"},{"issue":"5","key":"755_CR38","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1091\/mbc.e08-07-0726","volume":"20","author":"D del Toro","year":"2009","unstructured":"del Toro D, Alberch J, L\u00e1zaro-Di\u00e9guez F, Mart\u00edn-Ib\u00e1\u00f1ez R, Xifr\u00f3 X, Egea G, Canals JM. Mutant huntingtin impairs post-Golgi trafficking to lysosomes by delocalizing optineurin\/Rab8 complex from the Golgi apparatus. Mol Biol Cell. 2009;20(5):1478\u201392.","journal-title":"Mol Biol Cell"},{"issue":"4","key":"755_CR39","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1523\/JNEUROSCI.1870-13.2014","volume":"34","author":"YC Wong","year":"2014","unstructured":"Wong YC, Holzbaur EL. The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation. J Neurosci. 2014;34(4):1293\u2013305.","journal-title":"J Neurosci"},{"issue":"2","key":"755_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ncl.2020.01.010","volume":"38","author":"CM Stahl","year":"2020","unstructured":"Stahl CM, Feigin A. Medical, surgical, and genetic treatment of Huntington disease. Neurol Clin. 2020;38(2):367\u201378.","journal-title":"Neurol Clin"},{"issue":"18","key":"755_CR41","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1080\/14656566.2019.1674281","volume":"20","author":"DO Claassen","year":"2019","unstructured":"Claassen DO, Philbin M, Carroll B. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington\u2019s disease: a review of clinical trial data. Expert Opin Pharmacother. 2019;20(18):2209\u201321.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"755_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25(1):24\u201334.","journal-title":"Eur J Neurol"},{"issue":"1","key":"755_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"EM Coppen","year":"2017","unstructured":"Coppen EM, Roos RA. Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs. 2017;77(1):29\u201346.","journal-title":"Drugs"},{"issue":"7","key":"755_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s10529-020-02886-1","volume":"42","author":"H Ahmadian-Moghadam","year":"2020","unstructured":"Ahmadian-Moghadam H, Sadat-Shirazi MS, Zarrindast MR. Therapeutic potential of stem cells for treatment of neurodegenerative diseases. Biotechnol Lett. 2020;42(7):1073\u2013101.","journal-title":"Biotechnol Lett"},{"issue":"2","key":"755_CR45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/stem.3300","volume":"39","author":"AC Bachoud-Levi","year":"2021","unstructured":"Bachoud-Levi AC, Massart R, Rosser A. Cell therapy in Huntington\u2019s disease: taking stock of past studies to move the field forward. Stem Cells. 2021;39(2):144\u201355.","journal-title":"Stem Cells"},{"issue":"6","key":"755_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/cells8060595","volume":"8","author":"L Yu-Taeger","year":"2019","unstructured":"Yu-Taeger L, Stricker-Shaver J, Arnold K, Bambynek-Dziuk P, Novati A, Singer E, Lourhmati A, Fabian C, Magg J, Riess O, Schwab M, Stolzing A, Danielyan L, Nguyen HHP. Intranasal administration of mesenchymal stem cells ameliorates the abnormal dopamine transmission system and inflammatory reaction in the R6\/2 mouse model of huntington disease. Cells. 2019;8(6):595.","journal-title":"Cells"},{"issue":"4","key":"755_CR47","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/nan.12682","volume":"47","author":"RY Cheong","year":"2020","unstructured":"Cheong RY, Baldo B, Sajjad MU, Kirik D, Peters\u00e9n \u00c5. Effects of mutant huntingtin inactivation on Huntington disease-related behaviours in the BACHD mouse model. Neuropathol Appl Neurobiol. 2020;47(4):564\u201378.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"755_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-1-4939-9784-8_17","volume":"2056","author":"M Dabrowska","year":"2020","unstructured":"Dabrowska M, Olejniczak M. Gene therapy for Huntington\u2019s disease using targeted endonucleases. Methods Mol Biol. 2020;2056:269\u201384.","journal-title":"Methods Mol Biol"},{"issue":"6485","key":"755_CR49","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aba4624","volume":"367","author":"BR Leavitt","year":"2020","unstructured":"Leavitt BR, Tabrizi SJ. Antisense oligonucleotides for neurodegeneration. Science. 2020;367(6485):1428\u20139.","journal-title":"Science"},{"issue":"2","key":"755_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/brainsci11020129","volume":"11","author":"EA Spronck","year":"2021","unstructured":"Spronck EA, Vall\u00e8s A, Lampen MH, Montenegro-Miranda PS, Keskin S, Heijink L, Evers MM, Petry H, Deventer SJV, Konstantinova P, Haan M. Intrastriatal administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of Huntington disease pathology. Brain Sci. 2021;11(2):129.","journal-title":"Brain Sci"},{"issue":"3","key":"755_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/gt.2015.113","volume":"23","author":"B Connor","year":"2016","unstructured":"Connor B, Sun Y, von Hieber D, Tang SK, Jones KS, Maucksch C. AAV1\/2-mediated BDNF gene therapy in a transgenic rat model of Huntington\u2019s disease. Gene Ther. 2016;23(3):283\u201395.","journal-title":"Gene Ther"},{"issue":"9","key":"755_CR52","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.7150\/thno.18813","volume":"7","author":"LS Her","year":"2017","unstructured":"Her LS, Mao SH, Chang CY, Cheng PH, Chang YF, Yang HI, Chen CM, Yang SH. miR-196a enhances neuronal morphology through suppressing RANBP10 to Provide neuroprotection in Huntington\u2019s disease. Theranostics. 2017;7(9):2452\u201362.","journal-title":"Theranostics"},{"key":"755_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118952","volume":"267","author":"IO Yusuf","year":"2021","unstructured":"Yusuf IO, Chen HM, Cheng PH, Chang CY, Tsai SJ, Chuang JI, Wu CC, Huang BM, Sun HS, Chen CM, Yang SH. FGF9 induces neurite outgrowth upon ERK signaling in knock-in striatal Huntington\u2019s disease cells. Life Sci. 2021;267: 118952.","journal-title":"Life Sci"},{"issue":"5","key":"755_CR54","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1007\/s12035-020-02220-w","volume":"58","author":"IO Yusuf","year":"2021","unstructured":"Yusuf IO, Chen HM, Cheng PH, Chang CY, Tsai SJ, Chuang JI, Wu CC, Huang BM, Sun HS, Chen CM, Yang SH. Fibroblast growth factor 9 stimulates neuronal length through NF-kB signaling in striatal cell Huntington's disease models. Mol Neurobiol. 2021;58(5):2396\u2013406.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"755_CR55","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000491889","volume":"48","author":"IO Yusuf","year":"2018","unstructured":"Yusuf IO, Cheng PH, Chen HM, Chang YF, Chang CY, Yang HI, Lin CW, Tsai SJ, Chuang JI, Wu CC, Huang BM, Sun HS, Yang SH. Fibroblast growth factor 9 suppresses striatal cell death dominantly through ERK signaling in Huntington\u2019s disease. Cell Physiol Biochem. 2018;48(2):605\u201317.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"755_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ncb0309-228","volume":"11","author":"J Winter","year":"2009","unstructured":"Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228\u201334.","journal-title":"Nat Cell Biol"},{"issue":"5858","key":"755_CR57","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1126\/science.1149460","volume":"318","author":"S Vasudevan","year":"2007","unstructured":"Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318(5858):1931\u20134.","journal-title":"Science"},{"issue":"5","key":"755_CR58","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/stem.3155","volume":"38","author":"AS Channakkar","year":"2020","unstructured":"Channakkar AS, Singh T, Pattnaik B, Gupta K, Seth P, Adlakha YK. MiRNA-137-mediated modulation of mitochondrial dynamics regulates human neural stem cell fate. Stem Cells. 2020;38(5):683\u201397.","journal-title":"Stem Cells"},{"key":"755_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.mito.2021.04.013","volume":"59","author":"L Li","year":"2021","unstructured":"Li L, Voloboueva L, Griffiths BB, Xu L, Giffard RG, Stary CM. MicroRNA-338 inhibition protects against focal cerebral ischemia and preserves mitochondrial function in vitro in astrocytes and neurons via COX4I1. Mitochondrion. 2021;59:105\u201312.","journal-title":"Mitochondrion"},{"key":"755_CR60","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.omtn.2021.02.010","volume":"24","author":"L Zhang","year":"2021","unstructured":"Zhang L, Fang Y, Zhao X, Zheng Y, Ma Y, Li S, Huang Z, Li L. miR-204 silencing reduces mitochondrial autophagy and ROS production in a murine AD model via the TRPML1-activated STAT3 pathway. Mol Therapy Nucleic Acids. 2021;24:822\u201331.","journal-title":"Mol Therapy Nucleic Acids"},{"issue":"2","key":"755_CR61","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajhg.2013.05.025","volume":"93","author":"PH Cheng","year":"2013","unstructured":"Cheng PH, Li CL, Chang YF, Tsai SJ, Lai YY, Chan AW, Chen CM, Yang SH. miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet. 2013;93(2):306\u201312.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"755_CR62","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acschemneuro.1c00076","volume":"12","author":"X Meng","year":"2021","unstructured":"Meng X, Zhong J, Zeng C, Yung KKL, Zhang X, Wu X, Qu S. MiR-30a-5p regulates GLT-1 function via a PKC\u03b1-mediated ubiquitin degradation pathway in a mouse model of Parkinson\u2019s disease. ACS Chem Neurosci. 2021;12(9):1578\u201392.","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"755_CR63","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/stem.431","volume":"28","author":"RD Smrt","year":"2010","unstructured":"Smrt RD, Szulwach KE, Pfeiffer RL, Li X, Guo W, Pathania M, Teng ZQ, Luo Y, Peng J, Bordey A, Jin P, Zhao X. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells. 2010;28(6):1060\u201370.","journal-title":"Stem Cells"},{"issue":"5","key":"755_CR64","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.7150\/thno.47408","volume":"11","author":"ML Chen","year":"2021","unstructured":"Chen ML, Hong CG, Yue T, Li HM, Duan R, Hu WB, Cao J, Wang ZX, Chen CY, Hu XK, Wu B, Liu HM, Tan YJ, Liu JH, Luo ZW, Zhang Y, Rao SS, Luo MJ, Yin H, Wang YY, Xia K, Tang SY, Xie H, Liu ZZ. Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer\u2019s disease by enhancing autophagy. Theranostics. 2021;11(5):2395\u2013409.","journal-title":"Theranostics"},{"key":"755_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuroscience.2020.10.028","volume":"455","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Ge Y, Liu Q, Li YX, Chao X, Guan JJ, Diwu YC, Zhang Q. LncRNA BACE1-AS promotes autophagy-mediated neuronal damage through the miR-214-3p\/ATG5 signalling axis in Alzheimer\u2019s disease. Neuroscience. 2021;455:52\u201364.","journal-title":"Neuroscience"},{"issue":"20","key":"755_CR66","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1093\/hmg\/ddq311","volume":"19","author":"SS H\u00e9bert","year":"2010","unstructured":"H\u00e9bert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN, Sergeant N, Bu\u00e9e L, De Strooper B. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet. 2010;19(20):3959\u201369.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"755_CR67","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/glia.23450","volume":"66","author":"T Li","year":"2018","unstructured":"Li T, Wang J, Wang H, Yang Y, Wang S, Huang N, Wang F, Gao X, Niu J, Li Z, Mei F, Xiao L. The deletion of dicer in mature myelinating glial cells causes progressive axonal degeneration but not overt demyelination in adult mice. Glia. 2018;66(9):1960\u201371.","journal-title":"Glia"},{"issue":"22","key":"755_CR68","doi-asserted-by":"publisher","first-page":"8306","DOI":"10.1523\/JNEUROSCI.0567-11.2011","volume":"31","author":"J Tao","year":"2011","unstructured":"Tao J, Wu H, Lin Q, Wei W, Lu XH, Cantle JP, Ao Y, Olsen RW, Yang XW, Mody I, Sofroniew MV, Sun YE. Deletion of astroglial Dicer causes non-cell-autonomous neuronal dysfunction and degeneration. J Neurosci. 2011;31(22):8306\u201319.","journal-title":"J Neurosci"},{"issue":"1","key":"755_CR69","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2007.09.020","volume":"131","author":"JS Karres","year":"2007","unstructured":"Karres JS, Hilgers V, Carrera I, Treisman J, Cohen SM. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell. 2007;131(1):136\u201345.","journal-title":"Cell"},{"issue":"9","key":"755_CR70","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nn.2897","volume":"14","author":"R Sanuki","year":"2011","unstructured":"Sanuki R, Onishi A, Koike C, Muramatsu R, Watanabe S, Muranishi Y, Irie S, Uneo S, Koyasu T, Matsui R, Ch\u00e9rasse Y, Urade Y, Watanabe D, Kondo M, Yamashita T, Furukawa T. miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression. Nat Neurosci. 2011;14(9):1125\u201334.","journal-title":"Nat Neurosci"},{"issue":"3","key":"755_CR71","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1021\/acschemneuro.8b00683","volume":"10","author":"X Wu","year":"2019","unstructured":"Wu X, Meng X, Tan F, Jiao Z, Zhang X, Tong H, He X, Luo X, Xu P, Qu S. Regulatory mechanism of miR-543-3p on GLT-1 in a mouse model of Parkinson\u2019s disease. ACS Chem Neurosci. 2019;10(3):1791\u2013800.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"755_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12929-020-00636-z","volume":"27","author":"YY Wu","year":"2020","unstructured":"Wu YY, Kuo HC. Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases. J Biomed Sci. 2020;27(1):49.","journal-title":"J Biomed Sci"},{"issue":"1","key":"755_CR73","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13023-017-0742-x","volume":"12","author":"KH Chang","year":"2017","unstructured":"Chang KH, Wu YR, Chen CM. Down-regulation of miR-9* in the peripheral leukocytes of Huntington\u2019s disease patients. Orphanet J Rare Dis. 2017;12(1):185.","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"755_CR74","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/mds.26457","volume":"30","author":"AG Hoss","year":"2015","unstructured":"Hoss AG, Lagomarsino VN, Frank S, Hadzi TC, Myers RH, Latourelle JC. Study of plasma-derived miRNAs mimic differences in Huntington\u2019s disease brain. Mov Disord. 2015;30(14):1961\u20134.","journal-title":"Mov Disord"},{"issue":"53","key":"755_CR75","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1523\/JNEUROSCI.2390-08.2008","volume":"28","author":"AN Packer","year":"2008","unstructured":"Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9\/miR-9* regulates REST and CoREST and is downregulated in Huntington\u2019s disease. J Neurosci. 2008;28(53):14341\u20136.","journal-title":"J Neurosci"},{"issue":"6","key":"755_CR76","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.celrep.2018.07.017","volume":"24","author":"K Pircs","year":"2018","unstructured":"Pircs K, Petri R, Madsen S, Bratt\u00e5s PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Br\u00fcckner M, Lundh SH, Peters\u00e9n \u00c5, D\u00e9glon N, H\u00e9bert SS, Parmar M, Barker RA, Jakobsson J. Huntingtin aggregation impairs autophagy, leading to argonaute-2 accumulation and global microRNA dysregulation. Cell Rep. 2018;24(6):1397\u2013406.","journal-title":"Cell Rep"},{"issue":"4","key":"755_CR77","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1212\/WNL.0000000000004844","volume":"90","author":"ER Reed","year":"2018","unstructured":"Reed ER, Latourelle JC, Bockholt JH, Bregu J, Smock J, Paulsen JS, Myers RH. MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology. 2018;90(4):e264\u201372.","journal-title":"Neurology"},{"key":"755_CR78","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-6606-7-46","volume":"7","author":"J Kocerha","year":"2014","unstructured":"Kocerha J, Xu Y, Prucha MS, Zhao D, Chan AW. microRNA-128a dysregulation in transgenic Huntington\u2019s disease monkeys. Mol Brain. 2014;7:46.","journal-title":"Mol Brain"},{"issue":"11","key":"755_CR79","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.4103\/1673-5374.310673","volume":"16","author":"B Martinez","year":"2021","unstructured":"Martinez B, Peplow PV. Altered microRNA expression in animal models of Huntington\u2019s disease and potential therapeutic strategies. Neural Regen Res. 2021;16(11):2159\u201369.","journal-title":"Neural Regen Res"},{"issue":"3","key":"755_CR80","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12017-009-8063-4","volume":"11","author":"R Johnson","year":"2009","unstructured":"Johnson R, Buckley NJ. Gene dysregulation in Huntington\u2019s disease: REST, microRNAs and beyond. Neuromol Med. 2009;11(3):183\u201399.","journal-title":"Neuromol Med"},{"key":"755_CR81","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtn.2018.01.007","volume":"11","author":"M Fukuoka","year":"2018","unstructured":"Fukuoka M, Takahashi M, Fujita H, Chiyo T, Popiel HA, Watanabe S, Furuya H, Murata M, Wada K, Okada T, Nagai Y, Hohjoh H. Supplemental treatment for Huntington\u2019s disease with miR-132 that is deficient in Huntington\u2019s disease brain. Mol Ther Nucleic Acids. 2018;11:79\u201390.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"755_CR82","first-page":"36","volume":"48","author":"NS Caron","year":"2020","unstructured":"Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, Anderson LM, Ko S, Zhu X, van Deventer SJ, Evers MM, Konstantinova P, Hayden MR. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020;48(1):36\u201354.","journal-title":"Nucleic Acids Res"},{"key":"755_CR83","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","volume":"13","author":"EA Spronck","year":"2019","unstructured":"Spronck EA, Brouwers CC, Vall\u00e8s A, de Haan M, Petry H, van Deventer SJ, Konstantinova P, Evers MM. AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models. Mol Therapy Methods Clin Dev. 2019;13:334\u201343.","journal-title":"Mol Therapy Methods Clin Dev"},{"issue":"588","key":"755_CR84","doi-asserted-by":"publisher","first-page":"eabb8920","DOI":"10.1126\/scitranslmed.abb8920","volume":"13","author":"A Vall\u00e8s","year":"2021","unstructured":"Vall\u00e8s A, Evers MM, Stam A, Sogorb-Gonzalez M, Brouwers C, Vendrell-Tornero C, Acar-Broekmans S, Paerels L, Klima J, Bohuslavova B, Pintauro R, Fodale V, Bresciani A, Liscak R, Urgosik D, Starek Z, Crha M, Blits B, Petry H, Ellederova Z, Motlik J, van Deventer S, Konstantinova P. Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy. Sci Transl Med. 2021;13(588):eabb8920.","journal-title":"Sci Transl Med"},{"issue":"2","key":"755_CR85","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JHD-200002","volume":"9","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues FB, Wild EJ. Huntington\u2019s disease clinical trials corner: April 2020. J Huntingtons Dis. 2020;9(2):185\u201397.","journal-title":"J Huntingtons Dis"},{"issue":"3","key":"755_CR86","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1124\/pr.119.019026","volume":"72","author":"TJ Lee","year":"2020","unstructured":"Lee TJ, Yuan X, Kerr K, Yoo JY, Kim DH, Kaur B, Eltzschig HK. Strategies to modulate microRNA functions for the treatment of cancer or organ injury. Pharmacol Rev. 2020;72(3):639\u201367.","journal-title":"Pharmacol Rev"},{"key":"755_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejmech.2016.01.047","volume":"111","author":"M Durso","year":"2016","unstructured":"Durso M, Gaglione M, Piras L, Mercurio ME, Terreri S, Olivieri M, Marinelli L, Novellino E, Incoronato M, Grieco P, Orsini G, Tonon G, Messere A, Cimmino A. Chemical modifications in the seed region of miRNAs 221\/222 increase the silencing performances in gastrointestinal stromal tumor cells. Eur J Med Chem. 2016;111:15\u201325.","journal-title":"Eur J Med Chem"},{"issue":"12","key":"755_CR88","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1016\/j.ymthe.2018.08.022","volume":"26","author":"V Kumar","year":"2018","unstructured":"Kumar V, Kumar V, Luo J, Mahato RI. Therapeutic potential of OMe-PS-miR-29b1 for treating liver fibrosis. Mol Therapy. 2018;26(12):2798\u2013811.","journal-title":"Mol Therapy"},{"issue":"51","key":"755_CR89","doi-asserted-by":"publisher","first-page":"32370","DOI":"10.1073\/pnas.2016158117","volume":"117","author":"OA Patutina","year":"2020","unstructured":"Patutina OA, Gaponova Miroshnichenko SK, Sen\u2019kova AV, Savin IA, Gladkikh DV, Burakova EA, Fokina AA, Maslov MA, Shmendel EV, Wood MJA, Vlassov VV, Altman S, Stetsenko DA, Zenkova MA. Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency. Proc Natl Acad Sci U S A. 2020;117(51):32370\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"755_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.598617","volume":"14","author":"JE Amanzadeh","year":"2020","unstructured":"Amanzadeh JE, Esmaeili A, Rahgozar S, Noorbakhshnia M. Quercetin-conjugated superparamagnetic iron oxide nanoparticles protect AlCl(3)-induced neurotoxicity in a rat model of Alzheimer\u2019s disease via antioxidant genes, APP gene, and miRNA-101. Front Neurosci. 2020;14: 598617.","journal-title":"Front Neurosci"},{"key":"755_CR91","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jconrel.2016.06.005","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Paiva J, Santos T, Ferreira L, Bernardino L. MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson\u2019s disease. J Control Release. 2016;235:291\u2013305.","journal-title":"J Control Release"},{"issue":"3","key":"755_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193609","volume":"13","author":"C Saraiva","year":"2018","unstructured":"Saraiva C, Talhada D, Rai A, Ferreira R, Ferreira L, Bernardino L, Ruscher K. MicroRNA-124-loaded nanoparticles increase survival and neuronal differentiation of neural stem cells in vitro but do not contribute to stroke outcome in vivo. PLoS ONE. 2018;13(3): e0193609.","journal-title":"PLoS ONE"},{"issue":"2","key":"755_CR93","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP. Current clinical applications of in vivo gene therapy with AAVs. Mol Therapy. 2021;29(2):464\u201388.","journal-title":"Mol Therapy"},{"issue":"19","key":"755_CR94","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1093\/hmg\/ddz142","volume":"28","author":"KA Kaifer","year":"2019","unstructured":"Kaifer KA, Villal\u00f3n E, O\u2019Brien BS, Sison SL, Smith CE, Simon ME, Marquez J, O\u2019Day S, Hopkins AE, Neff R, Rindt H, Ebert AD, Lorson CL. AAV9-mediated delivery of miR-23a reduces disease severity in Smn2B\/-SMA model mice. Hum Mol Genet. 2019;28(19):3199\u2013210.","journal-title":"Hum Mol Genet"},{"key":"755_CR95","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.omtm.2019.10.008","volume":"15","author":"R Martier","year":"2019","unstructured":"Martier R, Sogorb-Gonzalez M, Stricker-Shaver J, H\u00fcbener-Schmid J, Keskin S, Klima J, Toonen LJ, Juhas S, Juhasova J, Ellederova Z, Motlik J, Haas E, van Deventer S, Konstantinova P, Nguyen HP, Evers MM. Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease. Mol Therapy Methods Clin Dev. 2019;15:343\u201358.","journal-title":"Mol Therapy Methods Clin Dev"},{"issue":"9","key":"755_CR96","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"MM Evers","year":"2018","unstructured":"Evers MM, Miniarikova J, Juhas S, Vall\u00e8s A, Bohuslavova B, Juhasova J, Skalnikova HK, Vodicka P, Valekova I, Brouwers C, Blits B, Lubelski J, Kovarova H, Ellederova Z, van Deventer SJ, Petry H, Motlik J, Konstantinova P. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant Huntingtin lowering in a Huntington\u2019s disease minipig model. Mol Ther. 2018;26(9):2163\u201377.","journal-title":"Mol Ther"},{"issue":"10","key":"755_CR97","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gt.2017.71","volume":"24","author":"J Miniarikova","year":"2017","unstructured":"Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, Rey M, Lubelski J, Evers MM, van Deventer SJ, Petry H, D\u00e9glon N, Konstantinova P. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease. Gene Ther. 2017;24(10):630\u20139.","journal-title":"Gene Ther"},{"issue":"6","key":"755_CR98","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/hum.2017.199","volume":"29","author":"EL Pfister","year":"2018","unstructured":"Pfister EL, DiNardo N, Mondo E, Borel F, Conroy F, Fraser C, Gernoux G, Han X, Hu D, Johnson E, Kennington L, Liu P, Reid SJ, Sapp E, Vodicka P, Kuchel T, Morton AJ, Howland D, Moser R, Sena-Esteves M, Gao G, Mueller C, DiFiglia M, Aronin N. Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington\u2019s disease. Hum Gene Therapy. 2018;29(6):663\u201373.","journal-title":"Hum Gene Therapy"},{"issue":"6","key":"755_CR99","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H, Ekstr\u00f6m K, Bossios A, Sj\u00f6strand M, Lee JJ, L\u00f6tvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654\u20139.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"755_CR100","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12974-020-01882-6","volume":"17","author":"X Chen","year":"2020","unstructured":"Chen X, Jiang M, Li H, Wang Y, Shen H, Li X, Zhang Y, Wu J, Yu Z, Chen G. CX3CL1\/CX3CR1 axis attenuates early brain injury via promoting the delivery of exosomal microRNA-124 from neuron to microglia after subarachnoid hemorrhage. J Neuroinflammation. 2020;17(1):209.","journal-title":"J Neuroinflammation"},{"key":"755_CR101","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2019.11.009","volume":"317","author":"G Kim","year":"2020","unstructured":"Kim G, Kim M, Lee Y, Byun JW, Hwang DW, Lee M. Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. J Control Release. 2020;317:273\u201381.","journal-title":"J Control Release"},{"issue":"1","key":"755_CR102","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12974-020-01745-0","volume":"17","author":"N Lai","year":"2020","unstructured":"Lai N, Wu D, Liang T, Pan P, Yuan G, Li X, Li H, Shen H, Wang Z, Chen G. Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice. J Neuroinflammation. 2020;17(1):74.","journal-title":"J Neuroinflammation"},{"key":"755_CR103","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.omtn.2017.04.010","volume":"7","author":"J Yang","year":"2017","unstructured":"Yang J, Zhang X, Chen X, Wang L, Yang G. Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia. Mol Therapy Nucleic Acids. 2017;7:278\u201387.","journal-title":"Mol Therapy Nucleic Acids"},{"issue":"1","key":"755_CR104","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14802\/jmd.16054","volume":"10","author":"ST Lee","year":"2017","unstructured":"Lee ST, Im W, Ban JJ, Lee M, Jung KH, Lee SK, Chu K, Kim M. Exosome-based delivery of miR-124 in a Huntington\u2019s disease model. J Mov Disord. 2017;10(1):45\u201352.","journal-title":"J Mov Disord"},{"issue":"9","key":"755_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137637","volume":"10","author":"MH Fu","year":"2015","unstructured":"Fu MH, Li CL, Lin HL, Tsai SJ, Lai YY, Chang YF, Cheng PH, Chen CM, Yang SH. The potential regulatory mechanisms of miR-196a in Huntington\u2019s disease through bioinformatic analyses. PLoS ONE. 2015;10(9): e0137637.","journal-title":"PLoS ONE"},{"issue":"9","key":"755_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162788","volume":"11","author":"T Kunkanjanawan","year":"2016","unstructured":"Kunkanjanawan T, Carter RL, Prucha MS, Yang J, Parnpai R, Chan AW. miR-196a ameliorates cytotoxicity and cellular phenotype in transgenic Huntington\u2019s disease monkey neural cells. PLoS ONE. 2016;11(9): e0162788.","journal-title":"PLoS ONE"},{"key":"755_CR107","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtm.2021.01.006","volume":"20","author":"C Eykens","year":"2021","unstructured":"Eykens C, Rossaert E, Duqu\u00e9 S, Ru\u00e9 L, Bento-Abreu A, Hersmus N, Lenaerts A, Kerstens A, Corthout N, Munck S, Van Damme P, Holt MG, von Jonquires G, Klugmann M, Van Den Bosch L, Robberecht W. AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS. Mol Ther Methods Clin Dev. 2021;20:508\u201319.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"755_CR108","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.theriogenology.2016.04.088","volume":"86","author":"PH Cheng","year":"2016","unstructured":"Cheng PH, Chang YF, Mao SH, Lin HL, Chen CM, Yang SH. Lentiviral transgenesis in mice via a simple method of viral concentration. Theriogenology. 2016;86(6):1427\u201335.","journal-title":"Theriogenology"},{"issue":"12","key":"755_CR109","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/dvg.20435","volume":"46","author":"SH Yang","year":"2008","unstructured":"Yang SH, Cheng PH, Sullivan RT, Thomas JW, Chan AW. Lentiviral integration preferences in transgenic mice. Genesis. 2008;46(12):711\u20138.","journal-title":"Genesis"},{"issue":"4","key":"755_CR110","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341\u20135.","journal-title":"Nat Biotechnol"},{"key":"755_CR111","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.biomaterials.2016.07.036","volume":"105","author":"E Jang","year":"2016","unstructured":"Jang E, Kim E, Son HY, Lim EK, Lee H, Choi Y, Park K, Han S, Suh JS, Huh YM, Haam S. Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy. Biomaterials. 2016;105:12\u201324.","journal-title":"Biomaterials"},{"issue":"10","key":"755_CR112","doi-asserted-by":"publisher","first-page":"16605","DOI":"10.18632\/oncotarget.15073","volume":"8","author":"A Tivnan","year":"2017","unstructured":"Tivnan A, Heilinger T, Ramsey JM, O\u2019Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH. Anti-GD2-ch14.18\/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget. 2017;8(10):16605\u201320.","journal-title":"Oncotarget"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-021-00755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-021-00755-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-021-00755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T17:19:03Z","timestamp":1725643143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-021-00755-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1186\/s12929-021-00755-1","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"27 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}